Data on the use of wireless capsule endoscopy (WCE) in younger children remain limited. However, this single centre study suggests that it is a relatively complication-free procedure that may be considered in younger children below 4 years of age, when small bowel pathology is suspected. We retrospectively reviewed the King's College Hospital WCE database between August 2009 and August 2011. Patients aged 4 years or younger were included in the study. Six children fulfilled the inclusion criteria. The indications for WCE were unexplained gastrointestinal tract (GIT) bleeding (n=4), chronic diarrhoea with (n=1) and without (n=1) GIT bleeding (n=1). All had an oesophagogastroduodenoscopy and an ileocolonoscopy before WCE. The mean age at the time of WCE was 2 years 6 months (range 1 year 7 months to 3 years 7 months). The mean weight at WCE was 13.3 kg (range 9-17 kg). Four children had a complete study.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369840 | PMC |
| http://dx.doi.org/10.1136/flgastro-2012-100163 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dual-Mechanism Gastroretentive Tablets with Encapsulated Gentian Root Extract.
Pharmaceutics
January 2025
Faculty of Pharmacy, University of Belgrade, 11221 Belgrade, Serbia.
This study aimed to develop gastroretentive tablets based on mucoadhesive-floating systems with encapsulated gentian (, Gentianaceae) root extract to overcome the low bioavailability and short elimination half-life of gentiopicroside, a dominant bioactive compound with systemic effect. The formulation also aimed to promote the local action of the extract in the stomach. Tablets were obtained by direct compression of sodium bicarbonate (7.
View Article and Find Full Text PDFDevelopment of Novel Oral Delivery Systems Using Additive Manufacturing Technologies to Overcome Biopharmaceutical Challenges for Future Targeted Drug Delivery.
Pharmaceutics
December 2024
Department of Biopharmaceutics and Pharmaceutical Technology, Institute of Pharmacy, University of Greifswald, Felix-Hausdorff-Strasse 3, 17489 Greifswald, Germany.
The development of targeted drug delivery systems for active pharmaceutical ingredients with narrow absorption windows is crucial for improving their bioavailability. This study proposes a novel 3D-printed expandable drug delivery system designed to precisely administer drugs to the upper small intestine, where absorption is most efficient. The aim was to design, prototype, and evaluate the system's functionality for organ retention and targeted drug release.
View Article and Find Full Text PDFInfluence of Dietary Fiber and Polyphenols During Pre-Gestation, Gestation, or Lactation on Intestinal Gene Expression.
Nutrients
January 2025
Physiology Section, Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Science, University of Barcelona (UB), 08028 Barcelona, Spain.
Background/objectives: Diet composition is important for health, especially during critical periods such as pre-gestation (P), gestation (G), or lactation (S), due to its potential impact not only on the mother but on the offspring. The Mediterranean diet includes many healthy foods rich in fiber and/or polyphenols, such as whole grains, fruits, vegetables, beans, and nuts. The present preclinical study assesses the impact of a diet rich in fiber and polyphenols (HFP diet) during one of those three periods (P, G, or S, three weeks each) on the rat gene expression of the small intestine obtained at the end of the lactation period.
View Article and Find Full Text PDFThe Stability-Indicating Ultra High-Performance Liquid Chromatography with Diode Array Detector and Tandem Mass Spectrometry Method Applied for the Forced Degradation Study of Ritlecitinib: An Appraisal of Green and Blue Metrics.
Pharmaceuticals (Basel)
January 2025
Department of Pharmaceutical Analysis, Faculty of Pharmacy and Biochemistry, University of Zagreb, 10000 Zagreb, Croatia.
Background/objectives: Janus kinase inhibitors open new horizons for small-molecule drugs in treating inflammatory bowel disease, with ritlecitinib demonstrating significant efficacy in clinical trials for ulcerative colitis and Crohn's disease. Ritlecitinib, a second-generation JAK3 inhibitor, is a novel therapeutic agent for alopecia areata and other autoimmune conditions.
Methods: A new stability-indicating UHPLC-DAD-MS/MS method was developed, validated, and applied for a forced degradation study of ritlecitinib under ICH guidelines.
Utilisation of the Innovative [18F]-Labelled Radiotracer [18F]-BIBD-071 Within HR+ Breast Cancer Xenograft Mouse Models.
Pharmaceuticals (Basel)
January 2025
Department of Nuclear Medicine, Beijing Tiantan Hospital, Capital Medical University, Beijing 100071, China.
Aromatase plays a crucial role in the conversion of androgens to oestrogens and is often overexpressed in hormone-dependent tumours, particularly breast cancer. [18F]BIBD-071, which has excellent binding affinity for aromatase and good pharmacokinetics, has potential for the diagnosis and treatment of aromatase-related diseases. The MCF-7 cell line, which is hormone receptor-positive (HR+), was used in the assessment of the novel [18F]-labelled radiotracer [18F]BIBD-071 via positron emission tomography (PET) imaging of an HR+ breast cancer xenograft model.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!